Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Terguride in hyperprolactinemia--experiences with 5 patients].

C Wüster1, A Scholz, A Schmelzle

  • 1Abteilung Innere Medizin, Medizinische Klinik, Heidelberg.

Klinische Wochenschrift
|April 2, 1990
PubMed
Summary

Terguride, a new dopamine agonist, effectively treats hyperprolactinemia with minimal side effects. This study found it well-tolerated in patients experiencing adverse reactions to other treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The SAVE FGR study: Short term variation Analysis versus Visual Evaluation of cardiotocography in early-onset Fetal Growth Restriction to trigger expedited birth - study protocol for a stepped wedge cluster randomized trial.

BMC pregnancy and childbirth·2026
Same author

Coherent Control of the Fine-Structure Qubit in a Single Alkaline-Earth Atom.

Physical review letters·2024
Same author

FG 7142: is this validated tool to study anxiety now forgotten?

Journal of neural transmission (Vienna, Austria : 1996)·2020
Same author

Classical dopamine agonists.

Journal of neural transmission (Vienna, Austria : 1996)·2019
Same author

Japanese medicine and Berlin: a very special and successful relationship.

Journal of neural transmission (Vienna, Austria : 1996)·2017
Same author

The "Madness" of Friedrich Hölderlin: an iatrogenic intoxication.

Journal of neural transmission (Vienna, Austria : 1996)·2017

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Hyperprolactinemia is often treated with dopamine agonists like bromocriptine or lisuride.
  • A significant portion of patients experience intolerable side effects, leading to treatment cessation.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of terguride, a novel dopamine agonist, in patients with hyperprolactinemia who could not tolerate conventional treatments.

Main Methods:

  • A study involving 5 patients (2 male, 3 female) with macro- or microprolactinoma.
  • Patients received terguride orally, with dosages adjusted up to 5 mg daily.
  • Treatment duration averaged 15.6 months.

Main Results:

  • All patients showed an initial decrease in prolactin levels after terguride administration.

Related Experiment Videos

  • Three patients achieved normoprolactinemia, and two with microprolactinoma regained normal menstrual cycles.
  • No significant side effects or changes in clinical chemistry or other pituitary hormones were observed.

    • Conclusions:

    • Terguride is an effective prolactin inhibitor with a favorable side effect profile.
    • It represents a valuable therapeutic option for hyperprolactinemia patients intolerant to existing dopamine agonists.